Sera Prognostics, Inc.
SERA

$288.03 M
Marketcap
$8.78
Share price
Country
$0.65
Change (1 day)
$12.36
Year High
$4.90
Year Low

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

marketcap

P/E ratio for Sera Prognostics, Inc. (SERA)

P/E ratio as of 2023: -5.15

According to Sera Prognostics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.15. At the end of 2022 the company had a P/E ratio of -0.88.

P/E ratio history for Sera Prognostics, Inc. from 2019 to 2023

PE ratio at the end of each year

Year P/E ratio
2023 -5.15
2022 -0.88
2021 -5.84
2020 -16.91
2019 -17.87